Pages that link to "Item:Q5701127"
From MaRDI portal
The following pages link to Non-parametric optimal design in dose finding studies (Q5701127):
Displaying 17 items.
- Optimal designs for estimating critical effective dose under model uncertainty in a dose response study (Q440031) (← links)
- Continual reassessment and related dose-finding designs (Q903292) (← links)
- Design efficiency in dose finding studies (Q956828) (← links)
- Unifying CRM and EWOC designs for phase I cancer clinical trials (Q1007501) (← links)
- Adaptive clinical trial designs for phase I cancer studies (Q2452091) (← links)
- Theoretical study of the continual reassessment method (Q2492919) (← links)
- Continual reassessment method for partial ordering (Q2893418) (← links)
- The role of minimal sets in dose finding studies (Q4559466) (← links)
- Simple benchmark for complex dose finding studies (Q5170208) (← links)
- Designs for Phase I Clinical Trials with Multiple Courses of Subjects at Different Doses (Q5434918) (← links)
- Evaluation of early phase dose finding algorithms in heterogeneous populations (Q6541920) (← links)
- A simulation-free approach to assessing the performance of the continual reassessment method (Q6617412) (← links)
- Improving safety of the continual reassessment method via a modified allocation rule (Q6627502) (← links)
- Extending the continual reassessment method to accommodate step-up dosing in phase I trials (Q6628516) (← links)
- Comment on: ``Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies'' (Q6629389) (← links)
- Surv-CRM-12: a Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progression (Q6629418) (← links)
- Dose finding studies for therapies with late-onset toxicities: a comparison study of designs (Q6629421) (← links)
